CEVR Participation at ISPOR Europe 2024

CEVR faculty will present their research during several discussion and poster sessions at ISPOR Europe 2024 in Barcelona:

Monday, November 19

• Breakout
  • 10:15 – 11:15: Should Health Technology Assessment Include the Bereavement Effect on Health-Related Quality of Life? What Difference Could It Make to Decisions About Life-Extending Treatments?
    • Moderator: Chris Skedgel, PhD, Office of Health Economics
    • Panelists: Tara Lavelle, PhD, Tufts University School of Medicine and Tufts Medical Center (CEVR); Becky Pennington, MSc, University of Sheffield; Saskia Knies, PhD, Zorginstituut Nederland
  • 1:45 – 2:45: Cure Models for Health Technology Assessment: Can They Be Trusted for Decision-Making?
    • Moderator: Megan John, MBBS, BSc, MRCGP, National Health Service and Chair of NICE Appraisal Committee D
    • Panelists: Nicholas Latimer, PhD, MSc, University of Sheffield & Delta Hat Limited; Federico Felizzi, PhD, Menarini GmbH; Melanie D. Whittington, PhD, MS, Tufts Medical Center (CEVR)
  • 5:00 – 6:00: Broader Value Elements: Methods to Quantify Each and Their Relevance for European Markets
    • Moderator: Richard Willke, PhD, Scintegral Health Economics, Lawrenceville, NJ, USA
    • Panelists: Jason Shafrin, PhD, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California; Melanie D. Whittington, PhD, MS, Tufts Medical Center (CEVR); Lotte Steuten, PhD, Office of Health Economics, London
• Educational Symposia
  • 3:15 – 4:15: Putting Breast Cancer Into a Societal Perspective: How Can We Account for Its Full Impact in HTA?
    • Moderator: Chris Skedgel, PhD, Office of Health Economics;
    • Speaker: Antonio Llombart Cussac, MD, PhD, Arnau de Vilanova Hospital;
    • Panelists: Melanie D. Whittington, PhD, MS, Tufts Medical Center (CEVR); Meindert Boysen, PharmD, MSc, Boysen Consulting International; Conchi 00 Biurrun, MA, Federación Española de Cáncer de Mama
• Poster
  • Poster Session 1: Factors Associated With the Inclusion of Societal Costs in Published Cost-Effectiveness Analyses, 2013-2022
    • Patil D, Liljas B, Neumann P, Li M
• Member Group Meetings
  • 10:15 – 11:15: Health Equity Research Special Interest Group
    • Speakers: Matt Griffiths, MA, MSc, Costello Medical, London; Ramiro Eugenio Gilardino, MD, MHS, MSc, MSD; and Melanie D. Whittington, PhD, MS, Tufts Medical Center (CEVR)

Tuesday, November 19

• Forums
  • 3:15 – 4:15: From Research to Policy to Patients: Measuring the Impact of Health Economics and Outcomes Research (HEOR)
    • Moderator: Jan E. Hansen, PhD, US Medical Affairs, Genentech
    • Speakers: Rob Abbott, CEO & Executive Director, ISPOR; Laura Pizzi, PharmD, MPH, Chief Science Officer, ISPOR; Lotte Steuten, PhD, Office of Health Economics; James Chambers, PhD, MPharm, Tufts Medical Center (CEVR)

Wednesday, November 20

• Breakout
  • 8:00 – 9:00: Equity in HTA: Exploring Methods and Their Role in Decision-Making
    • Moderator: Katharine Louise Cresswell, BSc (Int), MPH, Science Policy & Research Programme, National Institute for Health and Care Excellence
    • Panelists: Jeroen P Jansen, PhD, Center for Translational and Policy Research on Precision Medicine (TRANSPERS), University of California – San Francisco; Melanie D. Whittington, PhD, MS, Tufts Medical Center (CEVR),; Sandro Gsteiger, PhD, Global Access, F. Hoffmann-La Roche Ltd
  • 10:00 – 11:00: Incorporating Life Cycle Drug Pricing in Cost-Effectiveness Models: What Are the Opportunities and Risks for Health Systems and Manufacturers?
    • Moderator: Mark Sculpher, PhD, Centre for Health Economics, University of York, York, UK
      Panelists: Peter Neumann, ScD, Tufts Medical Center (CEVR); Beth Woods, BA, MSc, Centre for Health Economics, University of York; Dan Ollendorf, PhD, Institute for Clinical and Economic Review and Tufts Medical Center (CEVR)